The Use of DPP-4 Inhibitors in Short Bowel Syndrome

NCT02653131 | Terminated Phase 4

• 1 other identifier: GLP-1
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Conditions

Short Bowel Syndrome

Keywords

Short bowel syndrome

Outcome Measures

Primary Outcomes (1)

• Improvement of intestinal absorption

  the use of DPP-4 inhibitor results in the better intestinal absorption

  12 months

Study Arms (2)

DPP-4

EXPERIMENTAL

The administration of the DPP-4 inhibitor in the form of a pill once per day

Drug: Dipeptidyl peptidase-4 inhibitor

NO DPP

NO INTERVENTION

no therapy

Interventions

Dipeptidyl peptidase-4 inhibitor DRUG

Also known as: Sitagliptin

DPP-4

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• patients receiving home parenteral nutrition (HPN) because of short bowel syndrome for at least 12 months
• stable metabolic status
• benign disease

You may not qualify if:

• HPN \< 12 months
• metabolically unstable
• cancer as the reason for intestinal failure

Sponsors & Collaborators

• Stanley Dudrick's Memorial Hospital: lead

Study Sites (1)

Stanley Dudrick's Memorial Hospital

Skawina, 32-050, Poland

Location

Related Publications (1)

• Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):45S-52S. doi: 10.1177/0148607114526241. Epub 2014 Mar 10.

  PMID: 24615689 BACKGROUND

MeSH Terms

Conditions

Short Bowel Syndrome

Interventions

Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate

Condition Hierarchy (Ancestors)

Malabsorption Syndromes; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases; Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Protease Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Hypoglycemic Agents; Physiological Effects of Drugs; Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Pyrazines

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assoc. Prof.

Study Record Dates

• First Submitted: January 10, 2016
• First Posted: January 12, 2016
• Study Start: January 1, 2016
• Primary Completion: April 1, 2020
• Study Completion: April 1, 2020
• Last Updated: April 15, 2020

Record last verified: 2020-04

Data Sharing

• IPD Sharing: Will not share

Locations

PL (1)